• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

849
71
51
50
32

COUNTRY

31
13
13
12
12

PRICE

681
866
964
1,564

PUBLISHED

16
58
323
1,564

PRODUCT TYPE

959
499
86
16
2
2

Infectious Diseases

Antibiotics, antifungals, antivirals and other infectious disease pharmaceuticals account for a multibillion sector. The battle against contagious diseases takes places in a highly changeable environment, with a wealth of commercial opportunities arising from quickly emerging threats (e.g. avian flu) and the infectious disease and vaccination policies of national governments and international healthcare organisations. Keep track of the latest industry news and activity with the publications listed under Research and Markets’ Infectious Diseases category.

Our reports, books, and subscriptions will allow you to explore licensing, patents, forecasts, market trends, clinical trials, and drug pipelines. Leading players featured in our publications include Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Johnson & Johnson, Merck, Abbott, GlaxoSmithKline, Lilly, and more.

For publications about Infectious Disease Testing please visit the relevant category under Healthcare and Medical Devices. Show Less
Read more

PRODUCT TITLE

Bacterial Vaginosis - Pipeline Review, H1 2013

Bacterial Vaginosis - Pipeline Review, H1 2013 Summary 'Bacterial Vaginosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

June 2013
FROM

Hepatitis D - Pipeline Review, H1 2013

Hepatitis D - Pipeline Review, H1 2013 Summary 'Hepatitis D - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the...

June 2013
FROM

Bacteremia - Pipeline Review, H1 2013

Bacteremia - Pipeline Review, H1 2013 Summary 'Bacteremia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic...

June 2013
FROM

Hemorrhagic Fever - Pipeline Review, H1 2013

Hemorrhagic Fever - Pipeline Review, H1 2013 Summary 'Hemorrhagic Fever - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

June 2013
FROM

Tavaborole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Tavaborole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tavaborole (Dermatophytic Onychomycosis)...

June 2013
FROM

TDT-067 (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

TDT-067 (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “TDT-067 (Dermatophytic Onychomycosis) - Forecast...

June 2013
FROM

Ketoconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Ketoconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ketoconazole (Dermatophytic Onychomycosis)...

June 2013
FROM

Athlete's Foot (Tinea Pedis) Global Clinical Trials Review, H1, 2013

Athlete's Foot (Tinea Pedis) Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Athlete’s Foot (Tinea Pedis) Global Clinical Trials Review, H1, 2013 Global Clinical Trials...

June 2013
FROM

Griseofulvin (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Griseofulvin (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Griseofulvin (Dermatophytic Onychomycosis)...

June 2013
FROM

Fluconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Fluconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluconazole (Dermatophytic Onychomycosis)...

June 2013
FROM

Hepatitis A Global Clinical Trials Review, H1, 2013

Hepatitis A Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Hepatitis A Global Clinical Trials Review, H1, 2013" provides data on the Hepatitis A clinical trial scenario....

June 2013
FROM

Terbinafine (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Terbinafine (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Terbinafine (Dermatophytic Onychomycosis)...

June 2013
FROM

Luliconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Luliconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Luliconazole (Dermatophytic Onychomycosis)...

June 2013
FROM

Albaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Albaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Albaconazole (Dermatophytic Onychomycosis)...

June 2013
FROM

Itraconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Itraconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Itraconazole (Dermatophytic Onychomycosis)...

June 2013
FROM

Ciclopirox (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Ciclopirox (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ciclopirox (Dermatophytic Onychomycosis)...

June 2013
FROM

Adenovirus Infections Global Clinical Trials Review, H1, 2013

Adenovirus Infections Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Adenovirus Infections Global Clinical Trials Review, H1, 2013" provides data on the Adenovirus Infections...

June 2013
FROM

Warts Global Clinical Trials Review, H1, 2013

Warts Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Warts Global Clinical Trials Review, H1, 2013" provides data on the Warts clinical trial scenario. This report provides...

June 2013
FROM

PharmaPoint: Dermatophytic Onychomycosis (DO) - Current and Future Players

PharmaPoint: Dermatophytic Onychomycosis (DO) - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Dermatophytic Onychomycosis (DO) - Current and Future Players”....

June 2013
FROM

PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022 Summary Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection...

June 2013
FROM
Loading Indicator

Our Clients

Our clients' logos